Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last three months, 12 analysts have provided ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $198.25, with a high of $230.00 and a low of $169.00. Recent analyst actions include maintaining, raising, and lowering ratings and price targets.
June 05, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
12 analysts have rated Jazz Pharmaceuticals (NASDAQ:JAZZ) in the last three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $198.25, with a high of $230.00 and a low of $169.00. Recent analyst actions include maintaining, raising, and lowering ratings and price targets.
The majority of analysts have a bullish or somewhat bullish outlook on Jazz Pharmaceuticals, with no bearish ratings. The average price target is slightly lower than before, but the overall sentiment remains positive. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100